Compare Ascendis Pharma A/S (ASND) vs GoPro Inc (GPRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs GoPro Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while GoPro Inc trades at $0.76 (market cap $131.96M). The key difference: Ascendis Pharma A/S is far larger — about 134.4× GoPro Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| ASND | GPRO | |
|---|---|---|
Market Cap | $17.74B | $131.96M |
Sector | Health | Technology |
52-Week High | $277.18 | $2.88 |
52-Week Low | $163.32 | $0.64 |
Enterprise Value | $18.11B | $179.91M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
GoPro (GPRO) trades at $0.76, up 0.37% with neutral technical signals. The company faces severe financial distress with negative net income margins (-20.7%) and ROE (-236.05%), though valuation ratios appear low (P/E 4.56, P/S 0.2). Recent strategic review for potential sale and CEO's $20M financing provide near-term catalysts, but consecutive earnings misses and declining revenue ($652M in 2025) highlight operational challenges.
Outlook remains highly speculative with binary outcomes. The strategic sale process offers potential upside, but ongoing cash burn, negative equity, and competitive pressures present substantial downside risk. Analyst sentiment is mixed with 21% buy ratings, reflecting the company's precarious financial position and event-driven investment thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
